Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Condition:   Mesothelioma, Malignant Interventions:   Drug: Nivolumab;   Drug: Ramucirumab Sponsors:   Arkadiusz Z. Dudek, MD;   HealthPartners Institute Regions Cancer Care Center;   Eli Lilly and Company;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials